Status
Conditions
About
This prospective observational study aimed to evaluate the effects of supraphysiological estradiol (E2) levels, induced by gonadotropin therapy during IVF, on cardiac electrophysiological parameters. Sixty-two women aged 18-40 undergoing IVF treatment at Konya City Hospital between December 2024 and January 2025 were included.
ECG recordings were performed twice: once before gonadotropin stimulation and again on the day of hCG administration, when peak E2 levels were expected. Routine blood tests and hormone levels were also evaluated. Patients with obesity, cardiovascular disease, chronic illness, or medication use were excluded.
After treatment, significant increases were observed in PR interval, J-Tpeak, QTc, and Tp-e values. E2 changes showed a moderate negative correlation with QTc and a low positive correlation with J-Tpeak.
The results suggest that elevated E2 levels during IVF may affect cardiac electrophysiology, highlighting the need for careful monitoring in women with cardiac risk factors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Undergoing IVF treatment at Konya City Hospital between December 2024 and January 2025
No cardiac pathology based on cardiology consultation
Eligible for controlled ovarian stimulation using a short antagonist protocol
Provided informed consent
Exclusion criteria
Baseline estradiol level > 50 ng/L on day 2 of menstrual cycle
Presence of any known chronic diseases (e.g., diabetes mellitus, hypertension, rheumatologic disorders, thyroid disorders)
Use of any medications other than those used for IVF
Current smoker or alcohol user
Family history of cardiac disease or sudden cardiac death
Personal history of myocardial infarction, angina, heart failure, or any structural heart disease
History of cardiac surgery or coronary intervention
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal